Inhibition of citric acid- and capsaicin-induced cough by novel TRPV-1 antagonist, V112220, in guinea-pig by Leung, Sum Yee et al.
BioMed  Central
Page 1 of 5
(page number not for citation purposes)
Cough
Open Access Research
Inhibition of citric acid- and capsaicin-induced cough by novel 
TRPV-1 antagonist, V112220, in guinea-pig
Sum Yee Leung*1,4, Akio Niimi2, Alison S Williams1, Puneeta Nath1, F-
Xavier Blanc1, Q Thai Dinh3 and K Fan Chung1
Address: 1Thoracic medicine, National Heart & Lung Institute, Imperial College, London, UK, 2Department of respiratory medicine, Graduate 
school of medicine, Kyoto University, Japan, 3Department of internal medicine, Charite-Universitatsmedizin Berlin, Berlin, Germany and 
4Department of respiratory medicine, Chang Gung Memorial Hospital, Kaohsiung medical centre, Taiwan
Email: Sum Yee Leung* - sumyeeleung@hotmail.com; Akio Niimi - niimi@kuhp.kyoto-u.ac.jp; 
Alison S Williams - alison.williams@imperial.ac.uk; Puneeta Nath - puneeta.nath@novartis.com; F-Xavier Blanc - xavier.blanc@bct.aphp.fr; Q 
Thai Dinh - q-thai.dinh@charite.de; K Fan Chung - f.chung@imperial.ac.uk
* Corresponding author    
Abstract
Background: Cough reflex can be induced by the pepper extract capsaicin and by low pH in
guinea-pig airways. Transient receptor potential vanniloid-1 (TPRV-1) is expressed in the sensory
and afferent nerve fibres in airways.
Objective:  We hypothesized that a novel pyridazinylpiperazine analog TPRV-1 inhibitor can
effectively reduce cough reflex stimulated by citric acid and capsaicin.
Methods: Guinea pigs were injected with specific TPRV-1 inhibitor, V112220, a pyridazinylpiperazine analog of
N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl) tetrahydropyrazine-1(2H)-carbox-amide (BCTC) (3 mg/kg)
intra-peritoneally. One hour before cough response assessment. Coughs were recorded using a recorder
system that identified cough sound and accompanying expiratory flows, distinct from sneezes. Guinea-pigs
exposed to citric acid (0.4 M) and to capsaicin (10-4M) aerosols, in succession separately by 2 hours.
Results: V112220 significantly inhibited the number of coughs induced by citric acid (73 ± 11%, p
< 0.01) and capsaicin (70 ± 9.4%, p < 0.05) compared to vehicle control.
Conclusion: A novel pyridazinylpiperazine analog TPRV-1 inhibitor can inhibit the cough reflex,
induced by both low pH and capsaicin, suggesting that it could be clinically beneficial in treatment
of cough.
Introduction
Capsaicin is a potent tussive agent in most species includ-
ing humans. It activates a capsaicin receptor, transient
receptor potential vanilloid-1 (TRPV-1), which is a poly-
modal ion channel [1] that is activated by stimuli other
than capsaicin such as, heat, acid [2] and endogenous
compounds such as anandamide, bradykinin and endo-
cannabinoids [1,3,4]. Acidification of the airway in
guinea-pig also activates A-δ fibres and vagal C-fibre
nerves, partly through activation of TRPV-1 [5,6]. TRPV-1
expression has been found in epithelial nerves in guinea-
pig and in humans [7-9]; in chronic cough patients, the
expression of TRPV-1 in epithelial nerves is enhanced [7].
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Several antagonists of TRPV-1 have now been described
[10]. Capsazepine is one of the first antagonists described,
and blocks cough induced by capsaicin and citric acid [11-
13]. In addition, other antagonists such as iodo-resinifer-
atoxin and BCTC have also been shown to reduce capsai-
cin and citric acid cough in guinea-pigs [14,15]. We
investigated the effect of a novel and more selective TRPV-
1 antagonist [16-18], V112220, on cough induced by cap-
saicin and citric acid in the conscious guinea-pig.
Materials and methods
The protocols were approved by the Imperial College Bio-
Sciences Group and performed under a Project License
from the British Home Office, UK, under the Animals
(Scientific Procedures) Act 1986.
Animals
Pathogen free Male Hartley guinea pigs (600 – 700 g)
were used for the study. Animals were screened one week
before the in vivo cough examination.
Reagents
Materials used in the study including: V112220, a selec-
tive TRPV1 antagonist (Purdue Pharma, Ardsley, New
York); vehicle, 20% hydroxypropyl-β cyclodextrin (Sigma,
Dorset, UK); Procaterol hydrochloride (Sigma, Dorset,
UK); Citric Acid (Sigma, Dorset, UK) and Capsaicin
(Sigma, Dorset, UK).
Pre-screening of animals
Conscious guinea pigs were pre-screened to assess their
cough response to 0.4 M citric acid one week before the
cough study with V112220 or diluent. Low responders
(number of coughs < 3) and high responders (number of
coughs > 20) were excluded from the study. After pre-
screening, animals were allocated into 3 different groups,
the control group (n = 4) and two treatment groups
(either with V112220 or vehicle, n = 5).
In vivo cough measurements
Conscious animals were placed in a 4 L plethysmograph
which was equipped with an internal microphone and a
pressure transducer, and were connected to a Amplifier
Interface Unit series pre-amplifier (EMMS, Hants, UK).
Aerosols were generated with an ultrasonic nebuliser
(DeVilbiss, London, UK) which was connected to a Basic
Flow Supplier AIR 200 (EMMS, Hants, UK). Airflow was
set at 8 L/min. Coughs were detected in three ways: via the
microphone, via the pressure transducer and by observing
the guinea-pig behaviour which was also captured with an
external camera. Data acquisition was performed with the
eDacq (EMMS, Hants, UK) acquisition software.
Protocol
One week following screening, guinea pigs in the treat-
ment groups were injected with either 1 ml of vehicle or 3
mg/kg V112220 intra-peritoneally (i.p.) 1 hour before
cough response assessment. Each guinea pig received 0.1
mg/kg procaterol hydrochloride i.p. injection 10 minutes
prior to each cough assessment in order to minimise
bronchoconstriction. For cough assessment, animals were
exposed to 0.4 M citric acid for 10 min and a 10 min
cough response was recorded. Two hours following citric
acid inhalation, the same animal was exposed to 10-4 M
Capsaicin for 10 min and the cough response was
assessed.
Data analysis
Data were recorded as number of coughs per 10 min
assessment. Cough numbers of individual animal were
compared among pre-screening, following citric acid
inhalation and following capsaicin inhalation. Data from
the treatment groups were compared with the control
group. Mean values were statistically analyzed by one-way
analysis of variance (ANOVA) to evaluate significant dif-
ferences between groups. Values are expressed as means
and 95%CI, with p < 0.05 being considered significant.
Results
Pre-screening of animals
Guinea-pigs (n = 24) were pre-screened regarding their
cough response with citric acid. Ten guinea-pigs (8 low
and 2 high cough responders) were excluded and subse-
quently, fourteen guinea-pigs were divided into 3 groups.
No significant difference in baseline cough response was
noted among the 3 groups of guinea pigs. Figure 1 shows
the number of coughs in the 3 different groups for each
guinea-pig and the number of coughs following exposure
to citric acid and capsaicin at a later date either after no
treatment (control) or after vehicle or after V112220 treat-
ment.
Effect of V112220
Figure 2 shows the mean cough number with 95% CI for
the 3 groups of guinea-pigs for control, vehicle- and
V112220-treated group. Vehicle treatment did not signifi-
cantly change the number of coughs induced by either cit-
ric acid or capsaicin exposure. V112220 treatment (mean
± SEM: 2.6 ± 1.1; -0.4 to 5.6 coughs/10 min, p < 0.01) sig-
nificantly reduced the number of coughs induced by citric
acid compared to vehicle treatment (9.6 ± 1.6; 5.2 to 14.0
cough/10 min). V112220 treatment (2.6 ± 0.8; 0.3 to 4.9
coughs/10 min, p < 0.05) also significantly decreased the
number of coughs compared to vehicle treatment (8.6 ±
0.7; 6.7 to 10.5 cough/10 min) for capsaicin. V112220
reduced citric acid-induced cough response by 73 ± 11%
compared to vehicle treatment whereas capsaicin-induced
cough response was reduced by 70 ± 9.4%.Cough 2007, 3:10 http://www.coughjournal.com/content/3/1/10
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Discussion
Our study demonstrated that blockade of the TRPV-1
receptors with a selective inhibitor, V112220, which is a
pyridazinylpiperazine derivative, effectively decreased by
70% coughs evoked by citric acid or capsaicin aerosol
exposure in the guinea pig. This is in agreement with a
previous study using the earlier TRPV-1 antagonist, cap-
sazepine, which inhibited coughs induced by citric acid or
capsaicin but not coughs induced by 7% hypertonic saline
solution[12]. In addition, there have been other studies
with other TRPV-1 antagonists such as iodo-resinifera-
toxin and BCTC that have shown inhibition of cough
induced by citric acid and capsaicin in the guinea-pig
[14,15].
Number of coughs following citric acid or capsaicin exposure Figure 2
Number of coughs following citric acid or capsaicin exposure. Left panel show results from citric acid exposure while the right 
panel the results from capsaicin exposure. Data shown as mean ± 95% CI (*, ** p < 0.05 and 0.01 compared to vehicle treat-
ment).
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Number of coughs per 10 min in conscious guinea-pigs on pre-screen, following exposure to citric acid and to capsaicin Figure 1
Number of coughs per 10 min in conscious guinea-pigs on pre-screen, following exposure to citric acid and to capsaicin. Left 
panel shows the response in the control group, the central panel the response from vehicle-treated group, and the right panel 
the effect of treatment with V112220.
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Recently, 4-(2-pyridyl)piperazine-1-carboxamide ana-
logues as potent TRPV-1 antagonists have been developed
[19]. N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-
yl)tetrahydropyrazine-1(2H)-carboxamide (BCTC), a
member of that new chemical series, was a highly potent
TRPV-1 antagonist that effectively reverses the behavioral
effects of inflammatory and neuropathic pain in rats
[16,17,19] but is poor in metabolic stability, short half-
life, aqueous solubility, and in oral bioavailability [18].
Nevertheless, BCTC when administered intraperitoneally
(30 mg/kg) one hour before capsaicin cough challenge
caused an inhibition of capsaicin cough by 65% maxi-
mally [15]. A newer series of pyridazinylpiperazine com-
pounds with improved pharmaceutical and
pharmacological properties of BCTC was developed lead-
ing to V112220 which we used in this study. V112220 is
similar to V113886, another pyridazinylpiperazine deriv-
ative of BCTC [18]. The plasma half-life of this compound
after administration intravenously or by gavage is
reported to be around 6 hours in the rat [18]. For this rea-
son, we performed capsaicin challenge after citric acid
challenge on the basis that the compound would still
maintain significant plasma levels for many hours after
dosing. The degree of inhibition of capsaicin- and citric
acid-cough by V112220 we observed was similar with
70% reduction of the induced cough. However, capsaicin-
and citric acid-cough were not completely inhibited by
V112220. The incomplete inhibition, particularly of cap-
saicin-induced cough may indicate that higher dose of
V112220 may be needed for complete inhibition, since
cough response induced by capsaicin is presumed to be
entirely mediated by TRPV-1. However, further studies
with higher doses will be needed to answer this issue.
TRPV1 is sensitive to vanilloid molecules, including cap-
saicin. It can be activated by low extracellular pH
[2,6,20,21], and by the endocannabionid, anandamide
[22], lipoxygenase metabolites [23] and N-arachidonoyl-
dopamine [24], and also by a change in temperature [25].
TRPV1 is highly expressed in a subset of primary sensory
neurons of the trigeminal, vagal and dorsal root ganglia
with C- and A-δ fibres [9]. These receptors are polymodal
nociceptors. TRPV1 excites terminals of primary sensory
neurons and causes the initiation of action potentials of
reflex responses, such as cough in airways [26]. It may also
cause a series of neurogenic inflammation via antidromic
conduction of action potential to collateral nerve fibres
[26]. Capsaicin is one of the most tussigenic stimuli avail-
able in conscious animals and humans, and TRPV1 has
been identified as a possible component of the cough
receptor in guinea pigs and humans [27]. Inflammatory
stimuli such as prostaglandins, bradykinin, and nerve
growth factor may upregulate the expression and function
of TRPV-1 [28-30]. Chronic airway inflammation such as
in asthma or COPD may increase the sensitivity of TRPV-
1 to its agonists and trigger the cough reflex [27]. The
expression of TRPV-1 in the epithelial airway nerves of
patients with chronic persistent cough of diverse causes
and with an enhanced capsaicin cough response has a 3-
fold increase of TRPV-1 expression [7]. TRPV-1 receptors
may therefore contribute to the enhanced cough reflex
and the cough response in chronic persistent cough
Chronic persistent cough is a clinical problem, since anti-
tussives available to control cough are often not effective
[31]. More potent antitussives are needed. TRPV-1 antag-
onists may represent a potential class of antitussives that
could be useful in the control of chronic persistent cough.
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